Opthea Limited (OPT) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en South Yarra, VIC, Australia. El CEO actual es Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,.
OPT tiene fecha de IPO 2020-10-16, 33 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $4.24B.
Opthea Limited is a clinical-stage biopharmaceutical company based in South Yarra, Australia, focused on developing therapies for eye diseases. The company's pipeline is built on intellectual property targeting VEGF-C, VEGF-D, and VEGF Receptor-3 to address conditions involving abnormal blood and lymphatic vessel growth and vascular leakage. Its lead candidate, OPT-302, is a soluble VEGFR-3 inhibitor in clinical development for wet age-related macular degeneration and diabetic macular edema, designed to work alongside VEGF-A inhibitors for improved efficacy in retinal diseases.
